One year after arriving on the scene with a $120 million series A, ophthalmic gene therapy specialist Beacon Therapeutics Ltd. has raised $170 million in a series B.

Biopharmas raising money in public or private financings, including: Anbogen, Aptevo, Checkpoint, Kanvas, Recce.

Cartesian Therapeutics Inc.’s phase IIb study of its lead candidate, Descartes-08, in treating generalized myasthenia gravis (gMG) hit its primary endpoint while the company also notched a $130 million private placement equity financing.

Biopharmas raising money in public or private financings, including: Tiziana.

Biopharmas raising money in public or private financings, including: Cingulate, Elicio, Eliem, Eyenovia, Savara, Tenet, Waypoint.

Alumis Inc. began trading (NASDAQ:ALMS) earlier this morning, with the company’s IPO debuting at $16 per share to raise $210 million, with another $40 million coming through a concurrent private placement at the same price. That was the lower end of its previously announced price range, which had stretched as high as $18 per share.

Biopharmas raising money in public or private financings, including: Brainstorm, CASI, Gri Bio, Holoclara, Kala, Tonix, Vigil.

Biopharmas raising money in public or private financings, including: Allurion, CNS Pharmaceuticals, Diamedica, Taysha.

Biopharmas raising money in public or private financings, including: Alligator, Augustine, Curie.Bio, Formation, Zealand.